NCT07426003

Brief Summary

This research study is being conducted to determine the effects of enteral nutrition on healthy people. Enteral nutrition for the purpose of this study refers to the use of a specially developed formula taken by mouth that provides all essential nutrition either in the absence of food or to supplement the intake of foods. Enteral nutrition can be used for many reasons, such as to gain or lose weight, to treat food allergies, or to reduce inflammation in certain intestinal diseases. We would like to understand the effects of enteral nutrition in the absence of intestinal inflammation.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
12mo left

Started Apr 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress10%
Apr 2026May 2027

First Submitted

Initial submission to the registry

February 16, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 23, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

April 1, 2026

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2027

Last Updated

February 24, 2026

Status Verified

February 1, 2026

Enrollment Period

1 year

First QC Date

February 16, 2026

Last Update Submit

February 23, 2026

Conditions

Keywords

enteral nutritionhealthy volunteers

Outcome Measures

Primary Outcomes (1)

  • number of sitz markers at 72 hours

    Number of sitz markers that are present in an abdominal x-ray 72 hours after the participant takes the sitz mark capsule

    72 hours after taking the sitzmark capsule

Study Arms (2)

Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet

ACTIVE COMPARATOR

Participants will drink Kate Farms Peptide 1.5 for 60% of their calories and follow the Crohn's Disease Exclusion Diet for the remainder of their calories

Dietary Supplement: Kate Farms Peptide 1.5Other: Crohn's disease exclusion diet

Exclusive enteral nutrition

ACTIVE COMPARATOR

Participants will consume Kate Farms Peptide 1.5 exclusively except water, and coffee and tea with no sweetner or cream/milk for 3 days

Dietary Supplement: Kate Farms Peptide 1.5

Interventions

Kate Farms Peptide 1.5DIETARY_SUPPLEMENT

Kate Farms Peptide 1.5

Exclusive enteral nutritionPartial Enteral Nutrition and the Crohn's Disease Exclusion Diet

This study will use the components of the Crohn's disease exclusion diet Phase 1 which includes chicken breast, eggs, potatoes, bananas and apples

Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Must be able to read and understand English
  • Must be able to sign a consent form for the study

You may not qualify if:

  • BMI \<20 or \>30
  • Unintentional weight loss of \>10% in the last 3-6 months
  • Kidney disease
  • Diagnosis of cirrhosis
  • Taking diuretics
  • Anemia - Hemoglobin \<lower limit of normal in men or \<10 g/dL in women.
  • Taking iron supplements within 2 weeks for Visit 2.1
  • Taking prebiotic or probiotic supplements or any supplement including a multivitamin within 2 weeks of Visit 2.1
  • Taking antibiotics less than 4 weeks prior to Visit 2.1
  • Diarrhea in the 2 weeks prior to Visit 2.1
  • Diabetes mellitus
  • Diagnosis of congestive heart failure
  • Diagnosis of inflammatory bowel disease or celiac disease
  • Bowel resection other than an appendectomy
  • Pregnancy or breastfeeding
  • +6 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • James Lewis, MD, MSCE

    University of Pennsylvania

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor of Medicine and Epidemiology

Study Record Dates

First Submitted

February 16, 2026

First Posted

February 23, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

May 1, 2027

Last Updated

February 24, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Due to the small sample size, there is risk of participant identification. However, we will consider requests to access deidentified data on an individual basis and under a data use agreement.